← Back to Search

Kallikrein 5 Inhibitor

DS-2325a SC for Netherton Syndrome

Phase 1
Waitlist Available
Research Sponsored by Daiichi Sankyo
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 1: pre-dose & 4, 8, 24, 72, 96, 120, 144 hours (hr) post-dose; day 8 & 14: pre-dose; day 22: pre-dose & 4, 8, 24, 48, 72, 96, 120, 144, 168 hr post-dose; day 36, 43, 57, & 78

Summary

This trial is testing a new drug called DS-2325a for treating Netherton syndrome, a rare skin disorder. The drug works by blocking a protein that causes skin issues. The study will check if the drug is safe and how it behaves in the body when given to healthy people.

Eligible Conditions
  • Netherton Syndrome

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 1: pre-dose & 4, 8, 24, 72, 96, 120, 144 hours (hr) post-dose; day 8 & 14: pre-dose; day 22: pre-dose & 4, 8, 24, 48, 72, 96, 120, 144, 168 hr post-dose; day 36, 43, 57, & 78
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 1: pre-dose & 4, 8, 24, 72, 96, 120, 144 hours (hr) post-dose; day 8 & 14: pre-dose; day 22: pre-dose & 4, 8, 24, 48, 72, 96, 120, 144, 168 hr post-dose; day 36, 43, 57, & 78 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of Participants with Any Treatment-emergent Adverse Events Following Administration of DS-2325a
Secondary study objectives
Number of Participants Who Are Anti-Drug Antibody (ADA)-Positive (Baseline and Post-Baseline)
Pharmacokinetic Parameter Area Under the Concentration Curve (AUCtau)
Pharmacokinetic Parameter Average Concentration (Cavg)
+5 more

Trial Design

2Treatment groups
Experimental Treatment
Group I: Placebo SCExperimental Treatment1 Intervention
Participants who will be randomized to receive placebo as a subcutaneous (SC) injection.
Group II: DS-2325a SCExperimental Treatment1 Intervention
Participants who will be randomized to receive DS-2325a as a fixed dose subcutaneous (SC) injection (starting dose 300 mg).
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Placebo
1995
Completed Phase 3
~2670
DS-2325a
2022
Completed Phase 1
~90

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Daiichi SankyoLead Sponsor
412 Previous Clinical Trials
451,111 Total Patients Enrolled
2 Trials studying Netherton Syndrome
73 Patients Enrolled for Netherton Syndrome
Daiichi Sankyo, Inc.Lead Sponsor
389 Previous Clinical Trials
422,650 Total Patients Enrolled
2 Trials studying Netherton Syndrome
73 Patients Enrolled for Netherton Syndrome
Clinical DirectorStudy DirectorDaiichi Sankyo
18 Previous Clinical Trials
4,772 Total Patients Enrolled
1 Trials studying Netherton Syndrome
64 Patients Enrolled for Netherton Syndrome
~8 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top